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Bacterial bloodstream infections (BSI), both community acquired 
(CA) and healthcare associated (HA), are an important cause of 
neonatal and paediatric morbidity and mortality worldwide.[1] A 
meta-analysis of CA-BSI data from Africa in paediatric and adult 
patients established that non-typhoidal Salmonella, Escherichia coli, 
Staphylococcus aureus and Streptococcus pneumoniae are major 
pathogens, with CA-BSI associated mortality of 18% and a blood 
culture pathogen yield of 8.2%.[2] Data on HA neonatal and paediatric 
BSI (HA-BSI) in Africa are scant, but confirm high case fatality, a 
predominance of Klebsiella pneumoniae, E. coli and S. aureus, and 
high levels of antimicrobial resistance (AMR) among nosocomial 
pathogens.[3,4]
The increasing frequency of AMR among BSI pathogens is of 
great concern for African countries, where access to care and broad-
spectrum antimicrobials is often limited.[5-8] Important resistance 
phenotypes in BSI isolates include extended-spectrum β-lactamases 
(ESBL) and carbapenemase-producing Enterobacteriaceae. Data from 
a cross-sectional study at a South African (SA) children’s hospital 
showed the presence of ESBL in 83% of K. pneumoniae isolates,[9] 
along with the more recent emergence of carbapenem resistance due 
to carbapenemases.[10] Common carbapenemases include New Delhi 
metallo-β-lactamase-1 (NDM-1) and OXA-48-like enzymes.[11] The 
widespread and uncontrolled use of cephalosporins has contributed 
to the increased prevalence of ESBL-producing organisms, which 
may lead to increased BSI mortality, longer hospital stays and 
increased healthcare costs.[12-14]
The changing spectrum of pathogens, AMR patterns and clinical 
impact necessitates ongoing auditing, monitoring and publication of 
data on local pathogen profiles and antibiotic sensitivity patterns to 
inform clinical management and infection prevention efforts. [6,13,14] 
For neonates and children admitted to SA district hospitals, 
research on the epidemiology and AMR patterns of CA- and 
HA-BSI will inform development of appropriate empirical antibiotic 
recommendations. Furthermore, there are very limited data on 
paediatric clinicians’ prescribing practices to inform antimicrobial 
stewardship programmes at district hospitals.
Objective
To investigate the epidemiology of neonatal and paediatric BSI at 
Khayelitsha District Hospital (KDH) in Cape Town, SA, reporting 
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Background. The epidemiology of neonatal and paediatric community-acquired and healthcare-associated bloodstream infections (BSI) at 
South African (SA) district hospitals is under-researched.
Objective. Retrospective review of neonatal and paediatric BSI (0 - 13 years) at Khayelitsha District Hospital, Cape Town, SA, over 3 years 
(1 March 2012 - 28 February 2015).
Methods. We used laboratory, hospital, patient and prescription data to determine BSI rates, blood culture yield and contamination rates, 
pathogen profile, antimicrobial resistance, patient demographics, BSI outcome and antibiotic prescribing practice.
Results. From 7 427 blood cultures submitted, the pathogen yield was low (2.1%, 156/7 427) while blood culture contamination rates were 
high (10.5%, 782/7 427). Paediatric and neonatal BSI rates were 4.5 and 1.4/1 000 patient days, respectively. Gram-positive BSI predominated 
(59.3%); Staphylococcus aureus (26.8%) and Escherichia coli (21.6%) were common pathogens. The median patient age was 3 months, with 
a predominance of males (57.7%) and a 12.8% prevalence of HIV infection. Crude BSI-associated mortality was 7.1% (11/156), the death 
rate being higher in neonates than in infants and children (6/40 (15.0%) v. 5/116 (4.3%), respectively; p=0.03) and in patients with Gram-
negative compared with Gram-positive bacteraemia (6/66 (9.1%) v. 5/89 (5.6%), respectively; p=0.5). Most BSI episodes were community-
acquired (138/156; 88.5%), with high levels of extended-spectrum β-lactamase (ESBL) carriage among Klebsiella pneumoniae and E. coli 
isolates (5/5 (100%) and 8/33 (24.2%), respectively). Antimicrobial management of BSI was inappropriate in 30.6% of cases (45/147), 
including incorrect empirical antibiotic (46.7%), dual antibiotic cover (33.3%) and inappropriately broad-spectrum antibiotic use (17.8%).
Conclusions. Antimicrobial-resistant pathogens (notably ESBL-producing Enterobacteriaceae) were common in community-acquired BSI. 
Paediatric clinicians at district hospitals require ongoing training in antibiotic stewardship and blood culture sampling.
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BSI rates, pathogen profile, AMR patterns, risk factors for BSI-
associated mortality and antibiotic prescribing practice.
Methods
Setting
KDH serves an urban community of ~500 000 people. The popula-
tion is young (one-third <15 years of age) and mainly black African 
(99%), and most live in poor socioeconomic circumstances.[15] The 
hospital’s paediatric service comprises a 32-bed paediatric ward, a 
6-bed paediatric short-stay ward in the emergency centre, a 12-bed 
neonatal unit and a 10-bed kangaroo mother care (KMC) unit. 
Patients are admitted from the community via the emergency centre 
or by referral through a network of primary care providers known as 
community health clinics. Moderately and critically ill children are 
referred to tertiary-level hospitals in the Cape metropolitan region.
Investigation and management of BSI
Blood cultures are obtained from neonates and children presenting 
with clinical signs and/or risk factors for severe bacterial infection 
(including fever, lethargy, shock, meningism, pneumonia, HIV infec-
tion and severe acute malnutrition) or following clinical deterioration 
during hospitalisation with suspected healthcare-associated infection 
(HAI). Blood cultures performed at KDH are processed at the 
National Health Laboratory Service (NHLS) microbiology laboratory 
at Tygerberg Hospital, using the automated BacT/Alert system 
(BioMerieux, France). Positive cultures were identified using 
standard microbiological methods, and susceptibility testing was 
performed using either the standard Kirby-Bauer disc diffusion 
method or the automated Vitek 2 AES (BioMerieux, France). 
Susceptibility results were interpreted using Clinical and Laboratory 
Standards Institute criteria. Empirical antibiotic recommendations 
for CA severe bacterial infections include a third-generation 
cephalosporin (cefotaxime or ceftriaxone) for suspected meningitis 
and ampicillin for lower respiratory tract infections; gentamicin is 
added to ampicillin for infants and immunocompromised patients. 
Neonates receive penicillin G and gentamicin as first-line therapy 
or cefotaxime and ampicillin if meningitis is suspected. Empirical 
treatment for HA-BSI is piperacillin-tazobactam and amikacin, with 
escalation to meropenem in cases of suspected meningitis and in 
neonates and paediatric patients requiring transfer to tertiary care/an 
intensive care unit (ICU).
Data extraction and analysis
We retrospectively reviewed paediatric and neonatal BSI episodes at 
KDH between 1 March 2012 (when the hospital first opened) and 
28 February 2015 using laboratory records, hospital data, patient 
folders and antimicrobial prescription charts to determine BSI rates, 
blood culture yield and contamination rates, pathogen profile, AMR 
rates, patient demographics, BSI outcome and antibiotic prescribing 
practice. The total number of blood cultures submitted during the 
study period was determined, with extraction of all positive blood 
cultures from children (0 - 13 years) from the NHLS electronic 
database. Inpatient days for the paediatric, neonatal, KMC and short-
stay wards were obtained from the hospital data manager.
All positive blood culture isolates were classified as either 
pathogens or contaminants using the Centers for Disease Control 
and Prevention criteria.[16] Positive blood cultures isolating the 
same pathogen within 14 days were considered a single episode 
of BSI. Similarly, positive blood cultures with a pathogen and 
a contaminant were considered a single episode of BSI. In vitro 
susceptibility of pathogens was determined from the NHLS records, 
and AMR phenotypes were described using proposed criteria.[17] 
Isolates of E. coli and K. pneumoniae with reduced susceptibility to 
cefotaxime and/or ceftazidime were regarded as ESBL-producing 
organisms. No molecular tests were performed to confirm this, since 
these were retrospective data; however, plasmid-mediated ampC-like 
β-lactamases are very unusual in these organisms.
Positive blood cultures sampled <48 hours after hospital admission 
were considered to represent CA-BSI, whereas those obtained 
>48  hours after admission were classified as HA-BSI. Patients 
referred from a long-term healthcare institution or readmissions 
within 30 days of discharge were classified as HA-BSI. BSI and blood 
culture contamination rates were determined, with 95% confidence 
intervals (CIs). Demographic data were obtained from the laboratory 
records and hospital folder review, including age, weight, HIV 
status, antibiotic prescription record and outcome of hospitalisation. 
We calculated weight-for-age z-scores (WAZ) using World Health 
Organization anthropometric data and defined normal weight for age 
as WAZ ≥0, underweight for age as –2 - 0, moderately underweight as 
–2 - –3 and severely underweight as <–3.
Where patient folders could be located, antibiotic prescriptions for 
the BSI episode were systematically reviewed by the authors (who 
include paediatricians, paediatric infectious diseases specialists and 
a microbiologist). Appropriateness of the empirical and targeted 
antibiotic prescriptions and compliance with local antibiotic 
recommendations were evaluated by the authors to achieve consensus 
regarding the appropriateness of each patient’s empirical and targeted 
antibiotic prescription/s. Prescriptions were deemed appropriate 
if they were adequate to treat the patient’s clinical diagnosis and 
in compliance with local treatment guidelines. Prescriptions were 
considered inappropriate if they were unsuitable to treat the patient’s 
clinical diagnosis or in contravention of local treatment guidelines. 
Inappropriate prescriptions were subcategorised as follows: incorrect 
empirical antibiotic choice, dual antibiotic cover, and failure to use 
the most narrow-spectrum antibiotic available.
Statistical analysis
The BSI rate was calculated by dividing the total number of BSI 
episodes by the total inpatient days over the 3-year period. The 
pathogen rate and contamination rate were calculated by dividing 
the total number of pathogens and contaminants, respectively, by 
the total number of blood cultures submitted. Standard practice 
is for only a single blood culture bottle to be taken at each blood 
culture collection episode, and the total number of bottles therefore 
represented the total number of blood culture collection episodes. 
A χ2 test for linear trend was used to assess changes in neonatal and 
paediatric BSI rates over time. Continuous and categorical data were 
analysed using Student’s t-tests and Fisher’s exact tests/χ2 tests, as 
appropriate. Stata statistical software version 13.1 (StataCorp, USA) 
was used. To determine factors associated with mortality from BSI, 
binary logistic regression analysis was performed. Factors with a 
univariate p-value of <0.1 were entered into the model. A p-value of 
<0.05 was considered statistically significant.
Ethical approval
Ethical approval and waiver of individual informed consent was 
obtained from the Human Health Research Ethics Committee of 
Stellenbosch University (ref. no. S13/09/171) and the KDH ethics 
committee (ref. no. WC_2015RP15_794).
Results
Over the 3-year study period, the culture positivity rate was 12.6% 
(938/7 427 blood cultures), including 156 BSI episodes (2.1% pathogen 
yield) and 782 contaminated blood cultures (10.5%); contaminants 
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included coagulase-negative staphylococci 
(n=561, 71.7%), Micrococcus spp. (n=70, 
9.0%), non-pathogenic streptococci (n=38, 
4.9%), Corynebacterium spp. (n=32, 4.1%) 
and Bacillus spp. (n=31, 4.0%). Most 
contaminated blood cultures were submitted 
from the emergency centre (488/782, 62.4%). 
The neonatal and paediatric BSI rates were 
1.4/1 000 patient days (95% CI 0.9 - 1.9) and 
4.5/1 000 patient days (95% CI 3.7 - 5.3), 
respectively, with no significant change over 
the study period (Fig. 1).
Most blood culture samples from the 
patients with the 156 BSI episodes were 
submitted from the emergency centre 
(122/156, 78.2%), followed by the neonatal 
nursery (27/156, 17.3%) and the paediatric 
ward (7/156, 4.5%). The majority of 
episodes were CA-BSI (138/156, 88.5%), 
with 18 episodes (11.5%) of HA-BSI. Most 
BSI episodes were monomicrobial (145/156, 
92.9%), but 11 episodes (7.1%) were poly-
microbial, with two pathogens each (i.e. 
total pathogen yield of 167 BSI pathogens) 
(Table 1). Of the 11 polymicrobial BSI 
epi sodes, two were in neonates and nine 
in children. Gram-positive bacteria were 
the predominant pathogen type isolated 
(99/167, 59.3%), followed by Gram-
negative pathogens (67/167, 40.1%), with 
only one fungal BSI pathogen. The most 
frequent pathogens in neonates <28 days 
of age (n=40) were group B streptococci 
(20/40, 50.0%), S. aureus (7/40, 17.5%) and 
E.  coli (6/40, 15.0%). Among infants aged 
>28 days and children (n=116), the most 
prevalent BSI pathogens were S. aureus 
(38/116, 32.8%), E. coli (30/116, 25.9%) and 
S. pneumoniae (11/116, 9.5%).
Patients with BSI had a median age 
of 3 months (interquartile range (IQR) 
0.6 - 11 months) and a male predominance 
(57.7%) (Table 2). HIV status was unknown 
in only 9.6% (15/156); among the 141 patients 
with confirmed HIV status, the prevalence 
of HIV infection was 12.8% (18/141). Of 
the children 57.4% were HIV-exposed but 
uninfected (81/141). The most common 
BSI pathogens among HIV-infected chil-
dren were S. pneumoniae (n=5), followed 
by E. coli and S. aureus. The most prevalent 
comorbid conditions included prematurity 
(19.2%), malnutrition (severely under-
weight) (10.3%), tuberculosis (5.6%) and 
cerebral palsy (3.0%).
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Fig. 1. Trends in paediatric and neonatal BSI rates. (BSI = bloodstream infection; *Paediatrics BSI rate 
year 1 (BSI/inpatient days × 1 000): 39/9 234 × 1 000; year 2: 50/3 930 × 1 000; year 340/10 297 × 
1 000; †Neonatal BSI rate year 1: 8/5 046 × 1 000; year 2: 12/6 705 × 1 000; year 3: 7/7 504 × 1 000.)
Table 1. Microbiological profile of paediatric BSI episodes*
BSI episodes
Pathogens isolated from 156 BSI episodes
Isolates, n 
(N=167)
% of total BSI 
organisms* 
(N=167) % of group†
% of 
neonates 
(N=40)
% >28 
days of age 
(N=116)
% of deaths 
(N=11)
Gram-negative organisms 67
Enterobacteriaceae
Escherichia coli 36 21.6 53.6 15.0 25.9 27.3
Klebsiella pneumoniae 9 5.4 13.4 7.5 5.2 18.1
Salmonella non-typhi 4 2.4 6.0 0 3.4 0
Other‡ 5 3.0 7.5 5.0 2.6 0
Non-fermenting Gram-negative bacilli§ 5 3.0 7.5 0 4.3 0
Other
Neisseria meningitidis 6 3.6 9.0 0 5.2 9.1
Haemophilus influenzae 2 1.2 3.0 0 1.7 0
Gram-positive organisms 99
Staphylococcus aureus 45 26.8 45.5 17.5 32.8 9.1
Streptococcus pneumoniae 12 7.2 12.1 0 10.3 0
Group B streptococcus 26 15.6 26.3 50.0 5.2 27.3
Enterococcus spp. 10 6.0 10.1 5.0 6.9 9.1
Listeria monocytogenes 2 1.2 2.0 5.0 0 0
Other¶ 4 2.4 4.0 0 3.4 0
Fungi 1
Candida parapsilosis 1 0.6 100 0 0 0
BSI = bloodstream infection.
*145/156 (92.9%) BSI episodes monomicrobial, 11 (7.1%) polymicrobial with two pathogens each (total yield 167 BSI pathogens).
†Groups: Gram-negative organisms, Gram-positive organisms, fungi.
‡Other Enterobacteriaceae: Salmonella typhi, Shigella flexneri, Serratia marcescens, Citrobacter freundii.
§Non-fermenting Gram-negative bacilli: Acinetobacter baumannii, Pseudomonas aeruginosa, Chryseobacterium indologenes.
¶Other Gram-positives: viridans group streptococcus, group A streptococcus.
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Eighteen episodes (11.5%) of HA-BSI were documented, with a 
median hospital stay of 5 days (IQR 2 - 8) preceding HA-BSI onset. 
Ten HA-BSI episodes (55.6%) occurred in the neonatal nursery 
among premature babies. HA-BSI pathogens were K.  pneumon­
iae (n=4), E.  coli (n=3), group B streptococci (n=3), S. aureus 
(n=2), Enterococcus spp. (n=2), Pseudomonas aeruginosa (n=1), 
S.  pneumoniae (n=1), Serratia marcescens (n=1) and non-typhoidal 
Salmonella (n=1). Two patients died following episodes of E. coli and 
E. faecalis HA-BSI, at a median of 34 days from BSI onset.
The clinical impact of the 156 BSI episodes was severe: 86 patients 
(55.1%) required transfer to tertiary care, including 27 (17.3%) who 
required ICU admission for ventilation and/or inotropic support. 
The overall crude in-hospital BSI-associated mortality rate was 
7.1% (11/156), the case fatality rate being higher among neonates 
(0 - 28 days) compared with infants/older children (6/40 (15.0%) v. 
5/116 (4.3%), respectively; p=0.03). The median hospital stay from 
admission to death for patients with CA-BSI was 9 days (IQR 4 - 15). 
The BSI-associated crude mortality rate in HIV-infected children was 
higher than that in HIV-uninfected/HIV-unknown children (3/18 
(16.6%) v. 8/138 (5.8%), respectively; p=0.05). Mortality was higher 
among patients with Gram-negative BSI than among those with 
Gram-positive and fungal infections, but not significantly so (6/66 
(9.1%) v. 5/90 (5.6%), respectively; p=0.5). There was no difference 
in crude mortality rates between neonates/children with HA-BSI 
compared with CA-BSI (2/18 (11.1%) v. 9/138 (6.5%), respectively; 
p=0.62). On multivariate analysis, age <28 days and malnutrition 
(WAZ <–3) were significantly associated with mortality (odds ratio 
8.6 (95% CI 1.7 - 45.0) and 11.3 (95% CI 1.7 - 74.0), respectively; 
p=0.01). Among the children who died, most deaths occurred 
after transfer to the ICU (5/11, 45.5%), followed by deaths in the 
emergency centre (4/11, 36.4%) and the neonatal nursery (2/11, 
18.2%).
AMR rates were high for both CA-BSI and HA-BSI pathogens; 
among the CA-BSI pathogens, 8/33 (24.2%) E. coli and 5/5 (100%) 
K. pneumoniae were ESBL producers. Folder review of the 13 CA- 
ESBL BSI episodes found that only one of the 13 children had 
been admitted to hospital in the preceding 30 days, suggesting 
community acquisition of the ESBL-producing pathogens. Of the 
HA-BSI pathogens, all the K. pneumoniae (n=4) but none of the 
E. coli were ESBL producers. BSI-associated crude mortality was 
significantly higher among children with CA-BSI pathogens that 
produced ESBLs v. all other CA-BSI pathogens (3/13 (23.1%) v. 6/125 
(4.8%), respectively; p=0.04). Of the 42 S. aureus isolates, 4 (9.5%) 
were methicillin-resistant CA-BSI.
Meropenem provided greatest in vitro coverage for HA-BSI 
pathogens, with susceptibility in 16/18 (88.9%), followed by 
piperacillin-tazobactam (14/18, 77.8%) and amikacin (7/18, 38.9%). 
The institution’s recommended regimen for HAI (piperacillin-
tazobactam plus amikacin) provided good empirical coverage 
(16/18, 88.9%). Of CA-BSI pathogens, 68.1% were susceptible (in 
vitro) to first-line antibiotics (ampicillin and/or gentamicin) and 
69.6% were susceptible to ceftriaxone. No carbapenem-resistant 
Enterobacteriaceae, vancomycin-resistant enterococci or fluconazole-
resistant Candida species were isolated.
For the 156 BSI episodes, 147 complete patient folders and 
prescription charts (94.2%) were located for review. Nearly one-third 
of patients (45/147, 30.6%) were assessed through expert review 
as having received inappropriate antimicrobial therapy (empirical, 
targeted or both) (Table 3). The leading causes of inappropriate 
antibiotic use were incorrect empirical antibiotic choice (21/45, 
Table 2. Demographics of patients with BSI (N=156)
Variable LC-BSI (N=156) CA-BSI (N=138) HA-BSI (N=18) p-value
Gender (male), n (%) 90 (57.7) 78 (56.5) 12 (66.7) 0.41
Age (days), median (IQR) 94 (18 - 343) 113 (30 - 358) 15 (1 - 49) 0.006
Age category, n (%) 0.05
<28 days 40 (25.6) 31 (22.5) 9 (50.0)
28 - 364 days 77 (49.4) 71 (51.4) 6 (33.3)
1 - 5 years 26 (16.7) 23 (16.7) 3 (16.7)
>5 - 13 years 13 (8.3) 13 (9.4) 0
HIV status, n (%) 0.001
Infected 18 (11.5) 16 (11.6) 2 (11.1)
Negative, unexposed 73 (46.8) 57 (41.3) 16 (88.9)
Exposed, uninfected 50 (32.1) 50 (36.2) 0
Unknown 15 (9.6) 15 (10.9) 0
Ward at diagnosis, n (%) 0.001
Emergency unit 122 (78.2) 117 (84.8) 5 (27.8)
Paediatric ward 7 (4.5) 6 (4.3) 1 (5.6)
Neonatal nursery/KMC 27 (17.3) 15 (10.9) 12 (66.6)
Outcome, n (%) 0.47
Died 11 (7.0) 9 (6.5) 2 (11.1)
Survived 145 (93.0) 129 (93.5) 16 (88.9)
Impact, n (%) -
District hospital 70 (44.9) 63 (45.7) 7 (38.9)
Tertiary ward 59 (37.8) 51 (37.0) 8 (44.4)
Transferred to ICU 27 (17.3) 24 (17.3) 3 (16.7)
Duration of hospitalisation (days), median (IQR) 10 (5 - 17) 9 (4 - 14 21.5 (17 - 26) -
Time to HA-BSI onset (days), median (IQR) n/a n/a 5 (2 - 9) -
BSI = bloodstream infection; LC = laboratory confirmed; CA = community acquired; HA = hospital acquired; IQR = interquartile range; KMC = kangaroo mother care; ICU = intensive care unit; 
n/a = not applicable.
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46.7%), dual antibiotic cover (15/45, 33.3%) and failure to use the 
most narrow-spectrum antibiotic available (8/45, 17.8%).
Discussion
Our study documented pathogen yields markedly lower than 
reported from other African settings (8.2%).[2] Several factors, 
including district hospital level of care, antibiotics administered prior 
to admission and inadequate volumes of blood, may have contributed 
to the lower yield. According to the Integrated Management of 
Childhood Illness guidelines,[18] any child who fulfils the criteria 
for serious illness should receive intramuscular ceftriaxone prior to 
transfer, which may contribute to the lower pathogen yield observed 
and may also contribute to the proportionately higher prevalence of 
ESBLs in CA Enterobacteriaceae.
Of great concern is the high rate of blood culture contamination 
identified, which in addition to creating clinical uncertainty has a 
financial impact on the hospital owing to the costs of further testing 
and management, as well as implications for the patient, who has 
to undergo further investigations and a prolonged hospital stay. 
The contamination rate was more than three times higher than the 
internationally accepted rate of 3%.[19] This could be attributed to the 
difficulty in obtaining blood cultures from severely ill children, the 
busy emergency centre setting, staff and stock shortages, inadequate 
or irregular training of staff, high staff turnover, limited resources, 
and unfamiliarity with the blood culturing protocol. Factors known 
to contribute to increased blood culture contamination rates include 
young patient age (<36 months) and inexperienced physicians 
(trainees v. specialists).[19,20] Given the high contamination rates, 
urgent interventions such as regular training workshops on the 
correct sampling technique, feedback of monthly contamination rates 
to clinical staff, and intermittent checks of blood volume inoculum 
(by weighing culture bottles) should be implemented. In addition, all 
wards and the emergency centre should ensure that there is sufficient 
stock of sterile blood culture packs and consumables.
At our institution, Gram-positive BSI pathogens (59.3%) 
predominated, particularly among CA-BSI, and in contrast to many 
African BSI studies reporting Gram-negative predominance.[2,21] 
Gram-negative pathogens predominated in HA-BSI episodes, in 
keeping with findings of neonatal and paediatric BSI studies at two 
tertiary hospitals in Cape Town.[5,21,22] A large proportion of BSI 
patients (55.1%) required transfer to tertiary-level hospitals, which 
highlights the impact of BSI on children as well as the healthcare 
costs involved. Of note is the high number of CA ESBL organisms in 
our study, with a mortality rate three times higher than the overall 
crude mortality rate. Further scrutiny of CA ESBL BSI would have 
been beneficial in terms of determining the number of clinic visits 
with antibiotic administration prior to admission, and possible 
contributing factors leading to the emergence of resistance at a 
community level.
Knowledge of local organisms and their sensitivity profiles in a 
peripheral hospital is invaluable for development and revision of 
institutional antimicrobial guidelines. Regular review of AMR rates 
in neonatal and paediatric CA-BSI isolates will be required in view 
of the 68 - 70% current coverage of CA-BSI pathogens with empirical 
therapy (ampicillin/gentamicin or ceftriaxone). The institution’s 
empirical recommendations for HA-BSI provided high in vitro 
coverage, although the number of BSI in this category was very low.
Inappropriate empirical antibiotic choice accounted for almost half 
(46.7%) of the prescriptions that were evaluated as inappropriate. 
Incorrect initial antimicrobial choice has been associated with 
increased mortality in a study in SA ICUs (27% v. 11% when antibiotic 
choice was apppropriate).[23] In addition, 33.3% of prescriptions had 
dual antibiotic cover, where antibiotics were added to treatment 
plans and prescription charts were not amended. Based on the 
many inappropriate prescribing practices identified in this study, we 
recommend ongoing antibiotic stewardship audits, pharmacy audits 
and regular antibiotic stewardship clinical ward rounds to improve 
prescriber awareness and patient outcomes at district hospitals. 
Assessment of clinicians’ reasons for instituting, changing or deviating 
from recommended prescribing practice was problematic, owing to 
very poor documentation in the hospital records. Correct prescribing 
procedures need to be adhered to and documentation in clinical 
notes needs to be improved. At present, few structured antibiotic 
stewardship rounds are conducted in district-level hospitals owing 
to limited resources and expertise (i.e. lack of on-site microbiology, 
infectious diseases and/or clinical pharmacology personnel).
Similarly, improvements to documentation in clinical patient case 
notes should be highlighted to ensure continuity of care and assist in 
future audits. Healthcare professionals should take care to document 
the time of positive blood culture and the corresponding antibiotic 
choice. In the case of upscaling to second-line antibiotics, the 
clinical reason should be carefully documented. Prescription charts 
should be reviewed daily to ensure that all medications are correct 
and stopped timeously. The South African Antibiotic Stewardship 
programme prescription chart[24] should be used at district-level 
hospitals to improve prescribing practices. This will aid judicious 
prescribing practices and improve antibiotic stewardship rounds and 
audits at a district level.
Study limitations
Our study has several limitations: a relatively small number of 
BSI episodes and short study duration, which limit the ability 
to draw conclusions regarding antimicrobial susceptibility and 
prescribing trends; inability to observe blood culture inoculum 
volume and sampling technique (which influence blood culture 
yield and contamination rates); and inability to document recent 
hospitalisation and previous antibiotic exposures as variables affecting 
classification of CA- v. HA-BSI and blood culture yield, respectively. 
We reported a crude BSI-associated in-hospital mortality rate, 
and owing to the retrospective nature of the study it was not 
possible to determine whether deaths were due to the BSI alone or 
attributable to another event. The median number of days from blood 
culture specimen collection to death in the CA-BSI (9 days) and 
HA-BSI cohorts (34 days) suggests that additional factors may have 
contributed to our patients’ deaths. A further limitation was reliance 
Table 3. Antimicrobial management of BSI (N=147)*
n (%)
Appropriate 102 (69.4)
Inappropriate† 45 (30.6)
Incorrect empirical antibiotic prescribed 21/45 (46.7)
Dual antibiotic cover 15/45 (33.3)
Narrowest-spectrum agent not used 8/45 (17.8)
Inadequate documentation 7/45 (15.6)
Incorrect antibiotic switch 5/45 (11.1)
Blood culture result not followed up 4/45 (8.9)
Second-line protocol not followed 4/45 (8.9)
Earlier oral switch indicated but not made 2/45 (4.4)
Stock shortages 2/45 (4.4)
Initial escalation of antibiotic therapy required 1/45 (2.2)
BSI = bloodstream infection.
*9 folders could not be retrieved or had incomplete antimicrobial prescription records.
†In some cases there was more than one reason for assessing antimicrobial management of 
the BSI episode as inappropriate.
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on electronic records to evaluate antimicrobial prescription practices, 
with exclusion of nine records (5.8%) that were incomplete. Frequent 
antibiotic stock shortages influenced prescribing practice and may 
have resulted in delayed institution of targeted antibiotic therapy or 
de-escalation to narrow-spectrum agents. Despite these limitations, 
we believe that this first description of the epidemiology, outcome 
and therapy of neonatal and paediatric BSI at a large urban SA district 
hospital has provided valuable data to inform quality improvement in 
blood culture sampling and antibiotic stewardship.
Conclusions
Neonatal and paediatric BSI patterns at this SA district hospital show 
a predominance of Gram-positive, community-acquired pathogens 
and concerning levels of ESBL carriage among CA Enterobacteriaceae. 
Ongoing training of paediatric clinicians is needed to address high 
rates of blood culture contamination and inappropriate antibiotic 
prescribing practices.
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